Members Capital Advisors Inc’s Gilead Sciences GILD Stock Holding History

Members Capital Advisors Inc’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22,584	Closed	-$1.69M	–	40
2023 Q3	$1.69M	Hold	22,584	–	–	2.1%	11
2023 Q2	$1.74M	Hold	22,584	–	–	1.78%	18
2023 Q1	$1.87M	Hold	22,584	–	–	1.35%	28
2022 Q4	$1.94M	Hold	22,584	–	–	1.39%	31
2022 Q3	$1.39M	Hold	22,584	–	–	1.1%	42
2022 Q2	$1.4M	Hold	22,584	–	–	1.01%	47
2022 Q1	$1.34M	Hold	22,584	–	–	0.86%	60
2021 Q4	$1.64M	Buy	+22,584	New	+$1.56M	0.84%	50

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Members Capital Advisors Inc's GILD Position: Q4 2023 in Review

Members Capital Advisors Inc sold out of Gilead Sciences (GILD) in Q4 2023, closing a stake of 22,584 shares — an estimated $1.69M sold.

Members Capital Advisors Inc first reported a position in GILD in Q4 2021 and held it in 8 quarters. The position peaked at $1.94M in Q4 2022. 1,776 funds tracked by Wall St. Rank hold GILD as of Q4 2023.

Members Capital Advisors Inc reported no remaining Gilead Sciences position as of Q4 2023 after selling out during the quarter.
Members Capital Advisors Inc sold 22,584 Gilead Sciences shares in Q4 2023, an estimated $1.69M.
Members Capital Advisors Inc first reported a position in Gilead Sciences in Q4 2021 and held it in 8 quarters.
Members Capital Advisors Inc's Gilead Sciences position peaked at $1.94M in Q4 2022.
1,776 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2023.

Based on Members Capital Advisors Inc's 13F filing for Q4 2023, filed 2 Feb 2024.